about
Drug interaction prediction using ontology-driven hypothetical assertion framework for pathway generation followed by numerical simulation.Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.Effects of methimazole on the elimination of irinotecan.Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects.Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know.Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.Drug interactions in cancer therapy.Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumorsUnfavourable expression of pharmacologic markers in mucinous colorectal cancer.A systematic review on drug interactions in oncology.Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugsAn overview of the recent progress in irinotecan pharmacogenetics.Pharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy.Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.Irinotecan-induced muscle twitching from a possible drug interaction: A case report.Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs.Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
P2860
Q30482258-10C4130F-D665-4FAD-BE4C-08F5AE5C228DQ33183914-E2A5913C-8056-4B5A-B6EE-BACB84CCDBDFQ33201555-A0D149A3-592D-4508-B971-7BA4EBB8A7BBQ33647853-1E258FC4-DD87-4D3C-B160-F2A7D34C38C3Q33692838-E3F3DF60-7C33-44FB-873F-C0FCC7534FD6Q33712655-34651DB7-197A-43F6-B277-7CDF2868CDF1Q34504536-AC009BC5-2001-4B75-AD1B-5F1AFF2B3CCCQ35594029-C31F57FC-5192-4A82-904B-ABF5C35BC380Q35608207-46ECE2CB-B973-4D34-95AA-DDD38E041F80Q36120816-D0BEDCEC-A2CD-4801-9F75-ABF1461A3E24Q36271954-565A0DED-BB85-44AF-B5A5-0D53EAE47495Q36407286-6BC13C8B-051C-47CA-81C9-2184D7846560Q36516421-9B10BFED-4762-4B54-A8CC-A57062522363Q36569099-F70DFA3C-2ED2-4D3B-A72C-7C8B25431DB6Q36616168-C99CABAB-5C97-4244-8EE1-6164E72A6ECAQ36659821-AC1EC077-1CEE-4967-A036-51D162241F3DQ36746739-8B9702B0-3A03-4A0C-9C91-5E2B9BAA2FB4Q37710511-8C208D31-BCEA-44BF-B3E7-33817E7C89D6Q38024126-64AF826F-EEB8-43BA-A935-7E11F6BECF04Q38981028-77D5D891-B934-4974-A8CA-27228BD2F39EQ40107303-CE8C11BA-98D4-4205-BDCB-703C5811EBD9Q41910480-30DD18C9-7766-47E3-918E-A98893B0CD4FQ41962845-0C1B588D-036B-4567-A271-F08C8BCEE9BDQ43861920-F0A7CDE7-AE58-4193-BA2B-2F25186CAE1CQ45137094-83466A59-F105-4334-9941-2F536EAAE3F7Q50074569-249A87D9-D5A6-4E62-9030-40BE65175D34Q51826210-83DFA436-4169-4AEB-A30A-D00722D85BF7Q52362144-CD7FCE75-B0DC-4C2F-BB7D-1B4501A3B7E7Q53826969-D0E7A5F6-FBCF-41A0-B5AB-3EF51CDD4D49
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Modulation of irinotecan metabolism by ketoconazole.
@ast
Modulation of irinotecan metabolism by ketoconazole.
@en
type
label
Modulation of irinotecan metabolism by ketoconazole.
@ast
Modulation of irinotecan metabolism by ketoconazole.
@en
prefLabel
Modulation of irinotecan metabolism by ketoconazole.
@ast
Modulation of irinotecan metabolism by ketoconazole.
@en
P2093
P356
P1476
Modulation of irinotecan metabolism by ketoconazole.
@en
P2093
Diederik F S Kehrer
Jaap Verweij
Peter de Bruijn
Ron H J Mathijssen
P304
P356
10.1200/JCO.2002.08.177
P407
P577
2002-07-01T00:00:00Z